Brief: CStone Pharmaceuticals Announces Long-Term Survival Data For Cejemly
16/09/2024 11:25
Sept 16 (Reuters) - CStone Pharmaceuticals 2616.HK :
* LONG-TERM SURVIVAL DATA FOR CEJEMLY IN COMBINATION WITH
PLATINUM-BASED CHEMOTHERAPY
* DATA DEMONSTRATES BENEFIT IN PROGRESSION-FREE SURVIVAL,
OVERALL
SURVIVAL FOR SUGEMALIMAB COMBINED WITH CHEMOTHERAPY
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026